The rapid development of numerous, highly effective COVID-19 vaccines and therapies over the past year has been truly remarkable. While large biopharmaceutical players have made the headlines, many of these treatments were brought to market so expeditiously through partnerships with contract research organizations (CROs) and the decades of research and scientific expertise they bring to the drug discovery and development process.
Viroclinics-DDL is a leading specialized contract research organization, operating at the forefront of global infectious disease challenges. Founded in 2001 within the Erasmus Medical Center in Rotterdam, Viroclinics began as a niche laboratory within the field of influenza and over the years has grown in scale and expertise to provide services across numerous respiratory diseases and other viral targets, including RSV, MERS coronavirus, SARS-CoV, polio, hepatitis, measles and dengue. Today, Viroclinics serves the global biopharmaceutical industry with a full range of services to support and accelerate the market entry of innovative drugs, vaccines, and antivirals from discovery to launch. Since the beginning of our partnership with Viroclinics, we have been impressed by the impact and influence of the company’s scientific knowledge, longstanding experience and capability in respiratory infectious disease research services, all of which helped Viroclinics to mobilize quickly and play an influential role in the global fight against COVID-19. In 2022, Viroclinics was acquired by Cerba Healthcare, which we believe further underscores the pivotal role of CROs in the broader diagnostic and clinical trial laboratory services value chain.